MarketPulse

neurodegenerative diseases

4 articles
The Motley FoolThe Motley Fool··Sara Appino

Privium Fund Bets $5M on Denali Ahead of FDA Approval Win

Privium Fund Management acquires $5.07M stake in Denali Therapeutics following FDA approval of first commercial drug Avlayah for Hunter syndrome treatment.
DNLIclinical trialsneurodegenerative diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Institute Of Molecular And Clinical Ophthalmology Basel (Iob)

Scientists Develop MitoCatch: Engineered Protein Tech to Deliver Healthy Mitochondria to Damaged Cells

IOB scientists unveil MitoCatch, engineered technology delivering healthy mitochondria to damaged cells. Early data shows improved cell survival in disease models.
NVSheart failureneurodegenerative diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Ac Immune Sa

AC Immune, Lilly Expand Tau Partnership With $11M Upfront as Alzheimer's Race Heats Up

AC Immune and Eli Lilly amend collaboration to advance tau-targeting Alzheimer's candidates, with $11M upfront and IND studies starting mid-2026.
LLYACIUneurodegenerative diseasesAlzheimer's disease
BenzingaBenzinga··Prnewswire

Brainstorm Cell Therapeutics Completes $2M February Fundraising Round

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.
BCLIprivate placementcapital raise